MX2016009529A - Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos. - Google Patents

Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Info

Publication number
MX2016009529A
MX2016009529A MX2016009529A MX2016009529A MX2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A
Authority
MX
Mexico
Prior art keywords
hybridosomes
processes
compositions
production
same
Prior art date
Application number
MX2016009529A
Other languages
English (en)
Inventor
De Beer Joel
Original Assignee
Anjarium Biosciences Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anjarium Biosciences Ag filed Critical Anjarium Biosciences Ag
Publication of MX2016009529A publication Critical patent/MX2016009529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención proporciona un vehículo biocompatible híbrido (hibridosoma) que comprende elementos estructurales y bioactivos que se originan de al menos un módulo de liberación biocompatible (MLB) y al menos un módulo de encapsulación de fármacos modificado por ingeniería (MEFI) que comprende al menos un resto fusogénico ajustable. La invención proporciona además composiciones farmacéuticas que comprenden dichos hibridosomas, procesos para su fabricación, así como usos farmacéuticos y métodos farmacéuticos basados en los mismos.
MX2016009529A 2014-01-21 2015-01-20 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos. MX2016009529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929559P 2014-01-21 2014-01-21
PCT/IB2015/050436 WO2015110957A2 (en) 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Publications (1)

Publication Number Publication Date
MX2016009529A true MX2016009529A (es) 2016-10-17

Family

ID=52434912

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009529A MX2016009529A (es) 2014-01-21 2015-01-20 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
MX2021000174A MX2021000174A (es) 2014-01-21 2016-07-21 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000174A MX2021000174A (es) 2014-01-21 2016-07-21 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Country Status (13)

Country Link
US (3) US10561610B2 (es)
EP (2) EP3096741B1 (es)
JP (3) JP6598786B2 (es)
KR (3) KR102541164B1 (es)
CN (2) CN105934240B (es)
AU (3) AU2015208837B2 (es)
CA (1) CA2936514C (es)
DK (1) DK3096741T3 (es)
EA (1) EA037503B1 (es)
ES (1) ES2821758T3 (es)
MX (2) MX2016009529A (es)
WO (1) WO2015110957A2 (es)
ZA (1) ZA201604831B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
WO2014210448A1 (en) 2013-06-27 2014-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
KR102541164B1 (ko) 2014-01-21 2023-06-08 안자리움 바이오사이언시스 아게 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017136430A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
MA45051A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant la relaxine
CN106280533B (zh) * 2016-08-17 2018-03-09 赣南师范大学 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记
EP3292861A1 (en) * 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector
BR112019022016A2 (pt) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. Lipossomas fusogênicos, composições, kits e uso dos mesmos no tratamento do câncer
CN107084956B (zh) * 2017-05-05 2021-03-23 曲阜师范大学 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法
IL270496B1 (en) 2017-05-08 2024-07-01 Flagship Pioneering Innovations V Inc Intra-membrane aid preparations and their uses
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US20210085615A1 (en) * 2017-07-28 2021-03-25 National University Of Singapore Biomolecular composites comprising modified cell ghosts
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
CN118389609A (zh) * 2017-09-11 2024-07-26 加利福尼亚大学董事会 抗体介导的cas9向哺乳动物细胞的递送
WO2019066434A1 (ko) * 2017-09-30 2019-04-04 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
KR102008665B1 (ko) 2017-09-30 2019-08-08 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
US20200330616A1 (en) * 2017-11-13 2020-10-22 POLITECNICO Dl TORINO Biomimetic non-immunogenic nanoassembly for the antitumor therapy
WO2019104242A1 (en) 2017-11-22 2019-05-31 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
CN108287134B (zh) * 2017-12-28 2020-11-24 南京邮电大学 单颗粒生物探针及其等离子体生物存储器的构建方法
MX2020008542A (es) * 2018-02-17 2021-01-08 Flagship Pioneering Innovations V Inc Composiciones y métodos para el suministro de proteínas membranales.
EP3773742A4 (en) * 2018-04-06 2022-03-16 North Carolina State University CELL SET-MEDIATED CHECKPOINT INHIBITOR DELIVERY FOR CANCER IMMUNOTHERAPY
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN110437628B (zh) * 2018-05-04 2021-05-04 中国石油化工股份有限公司 一种改性剂母液和道路沥青及其合成方法
WO2019222403A2 (en) * 2018-05-15 2019-11-21 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020002540A1 (en) * 2018-06-28 2020-01-02 Astrazeneca Ab Exosome extracellular vesicles and methods of use
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
EP3880832A1 (en) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CN113631718A (zh) * 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
CN109620969B (zh) * 2019-01-30 2021-02-05 广东药科大学 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法
WO2021010586A1 (ko) * 2019-07-15 2021-01-21 (주)심플스틱 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법
KR20220044816A (ko) * 2019-08-12 2022-04-11 인티그레이티드 나노테라퓨틱스 아이엔씨. 하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
US20220288241A1 (en) * 2019-08-16 2022-09-15 Children's Medical Center Corporation Large scale production of exosome mimetics and uses thereof
CN112415081A (zh) * 2019-08-23 2021-02-26 四川大学 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法
KR102297995B1 (ko) * 2019-10-24 2021-09-02 포항공과대학교 산학협력단 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
EP3858332A1 (en) * 2020-01-31 2021-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bottom-up assembly of synthetic extracellular vesicles
CN116133652A (zh) * 2020-01-31 2023-05-16 摩登纳特斯有限公司 制备脂质纳米粒子的方法
WO2021186079A1 (en) * 2020-03-20 2021-09-23 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
CN112094809A (zh) * 2020-10-19 2020-12-18 军事科学院军事医学研究院环境医学与作业医学研究所 一种从血清或血浆中提取外泌体的方法
EP4320242A1 (en) 2021-04-08 2024-02-14 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
AU2022259546A1 (en) 2021-04-14 2023-11-16 Anjarium Biosciences Ag Fc-derived polypeptides
JP2024514157A (ja) 2021-04-14 2024-03-28 アンジャリウム バイオサイエンシズ エージー 薬物送達のためのペプチド、ナノ小胞、及びその使用
JP2024522149A (ja) * 2021-06-04 2024-06-11 インスティテュート フォー ベーシック サイエンス ナノベシクルリアクター及びその製造方法
WO2023001894A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023244084A1 (ko) * 2022-06-17 2023-12-21 주식회사 엠디뮨 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
EP2823809B1 (en) 2002-06-28 2016-11-02 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
JP5713325B2 (ja) 2009-04-17 2015-05-07 アイシス イノヴェイション リミテッド 遺伝物質の送達用の組成物
KR100950713B1 (ko) 2009-07-15 2010-03-31 (주)블루앤 음이온 발생기를 구비한 엘이디 램프
ES2579936T3 (es) 2009-08-20 2016-08-17 Sirna Therapeutics, Inc. Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
EP2485770A4 (en) 2009-10-08 2013-04-10 Merck Sharp & Dohme NEW CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR ADMINISTRATION OF OLIGONUCLEOTIDES
SG10201407996PA (en) 2009-12-23 2015-01-29 Novartis Ag Lipids, lipid compositions, and methods of using them
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP5149921B2 (ja) * 2010-02-19 2013-02-20 学校法人君が淵学園 癌細胞増殖抑制性ハイブリッド型リポソーム製剤
DK2555753T3 (en) * 2010-04-07 2018-11-26 California Inst Of Techn Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
US20110293701A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
CN103079592B (zh) * 2010-07-01 2015-10-21 浦项工科大学校产学协力团 使用来自细胞的微泡治疗和诊断癌症的方法
KR101130137B1 (ko) 2010-07-02 2012-03-28 연세대학교 산학협력단 발광다이오드 모듈
US20120058153A1 (en) 2010-08-20 2012-03-08 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
BR112013004585B1 (pt) 2010-09-20 2021-09-08 Merck Sharp & Dohme Corp Lipídeo catiônico, composição de lnp, e, uso de um lipídeo catiônico
CN103260611A (zh) 2010-09-30 2013-08-21 默沙东公司 用于寡核苷酸递送的低分子量阳离子脂质
CA2813024A1 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2012061259A2 (en) 2010-11-05 2012-05-10 Merck Sharp & Dohme Corp. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
WO2013048734A1 (en) * 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP2013128452A (ja) 2011-12-21 2013-07-04 Toshiba Corp 定量分析装置、定量分析方法、脂質膜小胞、及び試薬
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
US20160120818A1 (en) * 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
KR102541164B1 (ko) 2014-01-21 2023-06-08 안자리움 바이오사이언시스 아게 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
JP2024514157A (ja) 2021-04-14 2024-03-28 アンジャリウム バイオサイエンシズ エージー 薬物送達のためのペプチド、ナノ小胞、及びその使用
AU2022259546A1 (en) 2021-04-14 2023-11-16 Anjarium Biosciences Ag Fc-derived polypeptides
EP4326860A1 (en) 2021-04-20 2024-02-28 Anjarium Biosciences AG Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof

Also Published As

Publication number Publication date
US20160354313A1 (en) 2016-12-08
JP2019218349A (ja) 2019-12-26
KR102541164B1 (ko) 2023-06-08
KR102396026B1 (ko) 2022-05-09
AU2020227129A1 (en) 2020-10-01
KR102507475B1 (ko) 2023-03-07
MX2021000174A (es) 2021-03-25
JP6598786B2 (ja) 2019-10-30
US11484500B2 (en) 2022-11-01
CN112870163A (zh) 2021-06-01
DK3096741T3 (da) 2020-09-28
US10561610B2 (en) 2020-02-18
US20230181467A1 (en) 2023-06-15
AU2020227129B2 (en) 2022-06-30
AU2022218603A1 (en) 2022-09-15
US11944706B2 (en) 2024-04-02
WO2015110957A2 (en) 2015-07-30
EP3096741A2 (en) 2016-11-30
US20200222324A1 (en) 2020-07-16
KR20230039752A (ko) 2023-03-21
KR20220061286A (ko) 2022-05-12
CN105934240A (zh) 2016-09-07
AU2015208837B2 (en) 2020-06-18
AU2022218603B2 (en) 2024-10-03
CN105934240B (zh) 2021-02-09
EA037503B1 (ru) 2021-04-05
EP3096741B1 (en) 2020-09-02
CA2936514C (en) 2023-08-08
EP3791863A1 (en) 2021-03-17
ZA201604831B (en) 2018-05-30
JP2022101548A (ja) 2022-07-06
EA201691448A1 (ru) 2016-12-30
JP2017502997A (ja) 2017-01-26
WO2015110957A3 (en) 2015-12-03
CA2936514A1 (en) 2015-07-30
ES2821758T3 (es) 2021-04-27
KR20160110410A (ko) 2016-09-21
AU2015208837A1 (en) 2016-08-11
JP7046872B2 (ja) 2022-04-04

Similar Documents

Publication Publication Date Title
MX2021000174A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2016012846A (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
PH12016501841A1 (en) Immunosuppressant formulation
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
MX2020000738A (es) Composicion de suministro de farmaco.
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
HUE057593T2 (hu) Eljárás lényegében diasztereomeresen tiszta foszfor-diamidát oligomer elõállítására, az eljárással készített foszfor-diamidát oligomer és a foszfor-diamidát oligomert tartalmazó gyógyszerészeti készítmény
EP3679608A4 (en) TRIPLET-TRIPLET ANNIHILATION CONVERSION-ELEVATION SYSTEM, AND ASSOCIATED COMPOSITIONS AND METHODS FOR DRUG DELIVERY
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2016017124A (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
PH12016500847A1 (en) Multi-particulate drug delivery system
EP3650484A4 (en) ACTIVE SUBSTANCE RELEASE CARRIERS DIRECTED TO THE KIDNEYS
WO2015095659A3 (en) Indirubin solid dispersion composition
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
EP3368609A4 (en) MULTIFUNCTIONAL BIODEGRADABLE CARRIER FOR ACTIVE INJECTION